BRCA1 and gastric cancer: While the above considerations are based on our professional opinion, further study and expert discussion is urgently warranted to construct an optimal, evidence-based risk management strategy for GC risk among BRCA1/2 PV carriers, particularly as the incidence of GC in this population will likely increase over time as improvements in the detection and treatment of other at-risk malignancies (i.e., breast, ovarian, prostate, pancreatic) prolongs the overall lifespan of this cohort.